Artelo Biosciences, Inc. (ARTL, Financial) experienced a significant drop in its stock price, falling 5.39% to $1.15 with a trading volume of 18,680 shares and a turnover rate of 0.58%. The stock's amplitude reached 7.38% within the period.
Recent financial data for Artelo Biosciences reveals zero revenue, a net loss of $2.43 million, and an earnings per share of -$0.75. The company's gross profit stood at $0, with a price-to-earnings ratio of -0.35. Among the four institutions providing ratings, all recommend the stock as a buy, with no hold or sell ratings given.
The broader biotechnology industry, in which Artelo operates, saw an overall increase of 1.03%. Notable performers among related stocks included Celularity Inc, Cingulate Inc, and Tevogen Bio Holdings Inc, which recorded significant gains. Meanwhile, Ensysce Biosciences, Elevai Labs, and Cyclacel Pharmaceuticals showed high activity with turnover rates of 931.49%, 487.25%, and 119.18%, respectively. Stocks with notable amplitude included Celularity Inc, Klotho Neurosciences Inc, and 180 Life Sciences Corp, with amplitudes of 135.29%, 72.18%, and 68.89%.
Artelo Biosciences is a U.S.-based biopharmaceutical company focused on developing therapeutics targeting lipid signaling pathways, including the endocannabinoid system. Its strategic focus is on the discovery, licensing, development, and commercialization of treatments controlling this system. The company aims to introduce innovative cannabinoid-based therapies, leveraging proprietary technologies and projects derived from cannabis plants, synthetic cannabinoids, and new chemical entities. Artelo's flagship program is designed to develop a patent-protected combination cannabinoid therapy for a rare orphan disease.
